Abstract
The aim is to investigate the ultrasound and cytological characteristics of the thyroid nodules in Graves’ disease. Material and methods. Clinical, laboratory, ultrasound, cytological, immunocytochemical, cytochemical studies were performed in 59 patients with thyroid nodules in Graves’ disease. Clinical parameters
such as age of patients at the time of Graves’ disease debut, disease duration, and laboratory parameters were evaluated: thyroid-stimulating pituitary hormone levels and antibodies to the TSH receptor; ultrasonic characteristics — volume of thyroid gland, number of foci, echogenicity, echostructure, cystic changes and hyperechogenic inclusions. Cytological and immunocytochemical studies were performed on the FNA smears of foci, stained according
to Romanovsky. Indirect immunoperoxidase method with monoclonal antibodies to thyroid peroxidase, thyroglobulin and cytokeratin‑17 was used. Cytochemical studies were performed on non-fixed smears. Statistical analysis was performed by t — criterion of Student. Calculations are made in the program Statistica 10.0. Results. According to clinical study, patients with focal lesions were likely to have older age at the debut of Graves’ disease than patients with diffusely altered gland without lesions (p<0,05). Existence of focal formations were not related with such indicators as the duration of the disease, level of TSH and TSH receptor antibodies. Most patients had multisite goiter (88.1%). According to ultrasound examination all thyroid nodules had clear boundaries with a flat contour (100%), isoechogenic structure (87.5%) and cystic changes (67.8%). Cytological examination demonstrated that nodular goiter
(BSRTC‑2) was detected in 15 cases (25.42%), adenomatous nodular goiter (BSRTC‑2) — in 32 cases (54,24%), nodular goiter with B-cells (BSRTC‑2) — in 4 cases (6.78%); 6 cases (10.17%) were uninformative(BSRTC –1), in 1 case (1.69%) papillary carcinoma was detected, and in 1 — (1.69%) there was a suspicion of malignancy. Immunocytochemical and cytochemical examinations demonstrated high activity of thyroid peroxidase and thyroglobulin in FNA smears of
nodular and adenomatous goiter. At the same time, thyroid peroxidase was detected only for 18-22% of epithelial cells, Tg — in 69- 70% of thyrocytes, cytokeratyn‑17 for 4.7% of cells in FNA smears of papillary carcinoma which allowed to reveal cytological diagnosis. Conclusions. Focal lesions of the thyroid gland for Graves‘ disease are more commonly found in patients of older age at the time of the debut of Graves’ disease. For Graves disease the number of patients with multinodular goiter exceeds the number of patients with single focal entities (88.1% vs. 11.9%) and predominated features are clear boundaries, smooth contours and cystic changes. Cytological studies have shown a higher incidence of adenomatous nodular goiter (BSRTC –2) — 54.24% for Graves’ disease. Papillary carcinoma, according to the results of cytological examinations of FNA smears, was found in 1 case (1.69%), suspected malignancy also in 1 case (1.69%). Detection of cytological diagnosis of papillary carcinoma in the absence of clear cytological signs of malignancy, contributes to detection of high levels of cytokeratin‑17-positive cells and low content in the thyrocytes of thyroid peroxidase and thyroglobulin.
References
Priscila Carnerio Moreira Lima, Arnaldo Moura Neto, Marcos Antonio Tambascia. Risk factors assotiated with benign and malignant nodules sn autoimmune thyroid disease. ISRN Endocrinol. 2013:673146.
Belfiore A, Russo D, Vigneri R, Filetti S. Graves’ disease, thyroid, nodules and thyroid cancer. Clinical Endocrinology. 2001:55(6):711-718.
Pacini F, Elisei R, Di Coscio G, Anelli S, Macchia E, Concetti R, Miccoli P, Arganini M, Pinchera A. Thyroid carcinoma in thyrotoxic patients treated by surgery. The Journal of Endocrinologica lnvestigation. 1988;11(2):107-112.
Cantalamessa L, Baldini M, Orsatti A, Meroni L, Amodei V, Castagnone D. Thyroid nodules in graves disease and the risk of thyroid carcinoma. Archives of Internal Medicine. 1999:159(15):1705-1708.
Yu GP, Li JCL, Branovan D, McCormick S, Schantz SP. Thyroid cancer incidence and survival in the national cancer institute surveillance, epidemiology, and end results race/ethnicity groups. Thyroid. 2010;20(5):465-473.
Pazaitou-Panayiotou K, Michalakis K, Paschke R. Thyroid cancer in patients with hyperthyroidism. Hormone and Metabolic Research. 2012;44(4):255-262.
Дінець АВ, Фомін ПД, Гульчій МВ, Олійник ОБ. Клініко-морфологічні особливості папілярної мікрокарциноми щитоподібної залози на фоні хвороби Грейвса. Український медичний часопис. 2012;3:136-138. (Dinets’ AV, Fomin PD, Hul’chiy MV, Oliynyk OB. Clinical and morphological features of papillary microcarcinoma of the thyroid gland on the background of Graves’ disease. Ukrayins’kyy medychnyy chasopys. 2012;3:136-8).
Tronko M, Bogdanova T, Shpak V. Thyroid cancer in Ukraine during 1986-2014. Health effects of Chornobyl accident. Thirty years aftermath. Kyiv: DIA. 20166Ж: 85-103.
Bogdanova T, Saenko V, Shpak V. Long-term Analysis of the Incidence and Histopathology of Thyroid Cancer in Ukraine in adult patients who were children and adolescents at the time of the Chernobyl accident. In: Yamashita S, Thomas G, eds. Thyroid cancer and Nuclear accidents — long term after effects of Chernobyl and Fukushima. Amsterdam: Elsevier. 2017:67-76.
Bogdanova T, Zurnadzhy L, Nikiforov Y. Rebecca J Leeman-Neill, Tronko M, Chanock S, Mabuchi K, Likhtarov I, Kovgan L, Drozdovitch V, Little M, Hatch M, Zablotska L, Shpak V, McConnell R, Brenner A. Histopathological features of papillary thyroid carcinomas detected during four screening examinations of a Ukrainian-American cohort. Br J Cancer. 2015;113:1556-1564.
Ahuja AT, Ying M, Ho SY. Ultrasound of malignant cervical lymph nodes. Cancer Imaging. 2008;86:48-56.
Ying M, Ahuja A. Sonography of Neck Lymph Nodes. Part I: Normal Lymph Nodes. Clinical Radiology. 2003;58:351-8.
Robson C.D. Imaging of head and neck neoplasms in children. Pediatr Radiol. 2010;40(4):499-509
Nguyen Q, Lee E, Huang M. Diagnosis and Treatment of Patients with Thyroid Cancer. Am Health Drug Benefits. 2015;8(1):30-40.
Kini S. Guides to clinical aspiration biopsy. Thyroid. 1st ed. New York: Igaku-Shoin Medical Publishers Inc.—1987.
Clark D, Faquin W. Thyroid cytopathology. Essentials in cytopathology. New York: Springer, 2005.
Cibas ES, Ali SZ.; NCI Thyroid FNA State of the Science Conference. The Bethesda system for reporting thyroid cytopathology. Am. J. Clin. Pathol. 2009; 132(5):658-665.
Bozhok Y‚ Tavokina L, Epstein E. The new things in diagnostic of thyroid cancer. Optimal combination of morphological and immunocytochemistry research methods of punctious materials. Med Announcer. 1996,138:40-43.
Зелінська ГВ. Цитохімічне та імуноцитохімічне дослідження експресії тиреоїдної пероксидази в передопераційній діагностиці папілярного раку щитоподібної залози та його радіойодрезистентних метастазів. Онкологія. 2019; 21 (3): 1-6. (Zelins’ka HV. Cytochemical and immunocytochemical study of thyroid peroxidase expression in preoperative diagnosis of papillary thyroid cancer and its radioiodine-resistant metastases. Onkolohiya. 2019; 21 (3): 1-6).
Зелінська ГВ. Цитокератин № 17 і тиреоїдна пероксидаза в якості імуноцитохімічних маркерів доопераційного прогнозування радіойодрезистентності та ефективності радіойодтерапії папілярного раку щитоподібної залози. Онкологія. 2019; 21(1):31-5. (Zelinska HV. Cytokeratin № 17 and thyroid peroxidase as immunocytochemical markers of preoperative prediction of radioiodine resistance and efficacy of radioiodine therapy for papillary thyroid cancer. Onkolohiya. 2019; 21(1):31-5).
Kim WB, Han SM, Kim TY, et al. Ultrasonographic screening for detection of thyroid cancer in patients with Grave’s disease. Clinical Endocrinology. 2004; 60(6):719-725.
Dobyns BM, Sheline GE, Workman JB. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy. Follow up study. Journal of Clinical Endocrinology and Metabolism. 1974;38(6):976-998.
Filetti S, Belfiore A, Amir SM, et al. The role of thyroid-stimulating antibodies of Graves’ disease in differentiated thyroid cancer. The New England Journal of Medicine. 1988;318(12):753-759.
http://www.pathologyoutlines.com/topic/thyroidgraves.html
Scott R. Anderson M.D. Susan Mandel M.D., M.P.H. Virginia A. LiVolsi M.D. Prabodh K. Gupta M.D. Zubair W. Baloch M.D. Can cytomorphology differentiate between benign nodules and tumors arising in Graves’ disease? Diagnostic cytopathology. 2004;31(1):64-67.
Hang J, Lilo M, Bishop J, Ali S. Diagnostic accuracy of Fine Needle Aspiration in thyroid nodules arising in patients with Graves disease. Асta Cytologia. 2017;61:117-27.